Delivery Order SPE2DB24D9246-SPE2DB25FGUSS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $27,395.68 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector medications. This firm fixed-price delivery order was issued on August 19, 2025, with an ultimate completion date of September 10, 2025, and does not utilize a set-aside designation. The award represents a specific fulfillment under DMS Pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $1,712.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 150 mg/ml autoinjectors, with a period of performance through October 3, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to...
- The Defense Logistics Agency awarded a delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 mL auto-injector syringes on August 19, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a specific pharmaceutical product requirement to be delivered to Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park...
- The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order, awarded on August 14, 2025, with an ultimate completion date of September 5, 2025, represents a specific fulfillment under the company's larger Indefinite Delivery Contract with DLA valued at $499,999,999...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $1,712.23 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 mL auto-injector vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will deliver the product to the same location by the ultimate completion date of September 3, 2025. This delivery order was issued without a set-aside designation and is part of DMS Pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,273.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/mL auto-injector units. The delivery order, awarded on August 15, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed-price pricing and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order valued at $5,136.66 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml autoinjector on July 18, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, was issued without set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its facility in Park Ridge, IL. The award...
- The Defense Logistics Agency awarded a delivery order valued at $3,424.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector units. This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of September 9, 2025, represents a specific product fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The...
- The Defense Logistics Agency awarded a $12,841.65 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 24, 2025, for the supply of Xolair 150 mg/mL auto-injector medication. The contract, which must be completed by August 14, 2025, carries no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its facility in Park Ridge, IL 60068. This delivery order represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order by the Defense Logistics Agency (DLA) for Xolair 300 mg/2 ml auto-injector prefilled syringes. The contract, valued at $6,848.92 with a firm fixed-price structure, was awarded on August 13, 2025, with an ultimate completion date of September 4, 2025. This delivery order carries no set-aside designation and will be performed at the company's Park...
- SPE2DB24D9246Indefinite Delivery Contract
- SPE2DB24D9246-SPE2DB25FGUSSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,712.23 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on August 19, 2025, is scheduled for completion by September 10, 2025, with performance taking place in Park Ridge, Illinois. The contract utilizes no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, holds a significant role in the federal pharmaceutical supply chain as a key supplier to Defense Department healthcare facilities. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, which carries a $500 million potential value through November 2026. The parent IDC enables DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military health facilities nationwide. Xolair (omalizumab), a biologic therapy, represents the type of specialized pharmaceutical product covered under this broader framework, reinforcing DMS Pharmaceutical Group's established position as a critical distributor of prescription medications and specialty pharmaceuticals to Department of Defense medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/19/25 |